Ownership history in XTX Topco Ltd Β· 11 quarters on record
This page tracks every 13F SEC filing in which XTX Topco Ltd reported a position in ZENTALIS PHARMACEUTICALS INC (ZNTL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π XTX Topco Ltd underperformed the S&P 500 by β102.4% annually on this ZNTL position. Timing score: 50% (5/10 decisions correct). Average cost basis: $2.71. Maximum drawdown during holding period: β94.6%.
β Significantly underperformed the S&P 500 by 102.4% ann.
10 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
5 of 10 add/trim decisions correct
Best entry: $1.16 (2025 Q2) Β· Worst: $21.66 (2022 Q3)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
8 adds Β· 3 trims. Bought during 6 of 8 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.02% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size